These developments mark a key step in the company’s international expansion, the company states.

“The full launch of Mavatar Discovery in September will be a major milestone for us,” says Johan Juhlin, CEO and co-founder of Mavatar. “By making advanced analysis more accessible, researchers can focus where it really matters – on improving precision and finding the right treatments faster. Our US expansion is also a strategically important step. We now look forward to growing, further developing our platforms, and building strong partnerships to support our continued growth.”

Related article

AI and the 2024 Nobel Prizes: A Revolutionary Moment for Life Sciences

The 2024 Nobel Prizes in Chemistry and Physics reflect the revolutionary impact of artificial intelligence (AI) on life sciences. These awards, celebrating advancements in protein design and neural networks, demonstrate how AI is transforming how we approach drug discovery, personalized medicine, and healthcare management.

Actionable insights

Mavatar completed its latest funding round in late 2024. The company has since opened an office in Delaware, USA, initiated recruitment of new talent, and is currently in discussions around additional capital and strategic partnerships.

Mavatar Discovery is a platform designed to help researchers and life science companies accelerate the understanding of disease biology, identify novel biomarkers, and speed up drug development. Following a successful closed beta period, the company is now opening the platform to early access opportunities, it states. Mavatar Discovery can integrate and interpret vast amounts of transcriptomic data and turn them into actionable insights — in just minutes, the company promises.

Related article

Actionable Insights – The New Currency of Innovation

One of the most compelling trends in the life science sector today is the evolving role of data in decision-making processes. Life science companies are harnessing big data in ways that were once unimaginable, driven by technological advancements like AI, machine learning, and digital transformation. But as we look beyond 2025, it’s crucial to ask: How can these vast data resources be used to create actionable insights that lead to real-world impact? 

A second platform

Mavatar Discovery is powered by the company’s Deep Integrated Network Analysis (DINA) framework, which integrates and analyzes large volumes of biomedical data from diverse sources.

In 2026, Mavatar will launch a second platform, Mavatar Precision, a clinical decision support tool that enables tailored treatment recommendations based on each patient’s unique biology. By analyzing biomarker data from a blood sample, the platform can match a patient to a digital twin – a virtual model that mirrors the molecular profile of the patient’s disease, it describes. In this model, different treatment options are simulated to identify which therapy is likely to be the best one.